<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:41:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6015379" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6015379</identifier>
        <datestamp>2018-07-05</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6015379</article-id>
              <article-id pub-id-type="pmcid">PMC6015379</article-id>
              <article-id pub-id-type="pmc-uid">6015379</article-id>
              <article-id pub-id-type="pmid">29776960</article-id>
              <article-id pub-id-type="pmid">29776960</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.117.008517</article-id>
              <article-id pub-id-type="publisher-id">JAH33201</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Preventive Cardiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of Combined Treatment With Folic Acid, Vitamin B<sub>6</sub>, and Vitamin B<sub>12</sub> on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women</article-title>
                <alt-title alt-title-type="left-running-head">Christen et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah33201-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Christen</surname>
                    <given-names>William G.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <address>
                    <email>wchristen@rics.bwh.harvard.edu</email>
                  </address>
                  <xref ref-type="aff" rid="jah33201-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah33201-cr-0002" contrib-type="author">
                  <name>
                    <surname>Cook</surname>
                    <given-names>Nancy R.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref ref-type="aff" rid="jah33201-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33201-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah33201-cr-0003" contrib-type="author">
                  <name>
                    <surname>Van Denburgh</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <xref ref-type="aff" rid="jah33201-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah33201-cr-0004" contrib-type="author">
                  <name>
                    <surname>Zaharris</surname>
                    <given-names>Elaine</given-names>
                  </name>
                  <degrees>BA</degrees>
                  <xref ref-type="aff" rid="jah33201-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah33201-cr-0005" contrib-type="author">
                  <name>
                    <surname>Albert</surname>
                    <given-names>Christine M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33201-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33201-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah33201-cr-0006" contrib-type="author">
                  <name>
                    <surname>Manson</surname>
                    <given-names>JoAnn E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33201-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah33201-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah33201-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Preventive Medicine</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Brigham and Women's Hospital</institution>
                <institution>Harvard Medical School</institution>
                <named-content content-type="city">Boston</named-content>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah33201-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiovascular Medicine</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Brigham and Women's Hospital</institution>
                <institution>Harvard Medical School</institution>
                <named-content content-type="city">Boston</named-content>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah33201-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Epidemiology</named-content>
                <institution>Harvard School of Public Health</institution>
                <named-content content-type="city">Boston</named-content>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> William G. Christen, ScD, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Ave E, Boston, MA 02215‐1204. E‐mail: <email>wchristen@rics.bwh.harvard.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>5</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>05</day>
                <month>6</month>
                <year>2018</year>
              </pub-date>
              <volume>7</volume>
              <issue>11</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.2018.7.issue-11</issue-id>
              <elocation-id>e008517</elocation-id>
              <history>
                <date date-type="received">
                  <day>31</day>
                  <month>12</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>16</day>
                  <month>4</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-7-e008517.pdf"/>
              <abstract id="jah33201-abs-0001">
                <sec id="jah33201-sec-0001">
                  <title>Background</title>
                  <p>The aim of this study was to determine whether reducing plasma homocysteine concentrations with long‐term, combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> alters plasma biomarkers of inflammation and endothelial dysfunction in women at increased risk of cardiovascular disease.</p>
                </sec>
                <sec id="jah33201-sec-0002">
                  <title>Methods and Results</title>
                  <p>We conducted a blood substudy of 300 treatment‐adherent participants (150 in the active treatment group, 150 in the placebo group) in the WAFACS (Women's Antioxidant and Folic Acid Cardiovascular Study), a randomized, double‐blind, placebo‐controlled trial testing a daily combination of folic acid (2.5 mg), vitamin B<sub>6</sub> (50 mg), vitamin B<sub>12</sub> (1 mg), or matching placebo, in cardiovascular disease prevention among women at increased risk of cardiovascular disease. Plasma concentration of 3 biomarkers of inflammation (C‐reactive protein, interleukin‐6, and fibrinogen) and a biomarker of endothelial dysfunction (intercellular adhesion molecule 1) were measured at baseline and at the end of treatment and follow‐up. After 7.3 years of combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub>, homocysteine concentrations were reduced by 18% in the active treatment group as compared with the placebo group (<italic>P</italic>&lt;0.001). However, there was no difference between treatment groups in change in blood concentration from baseline to follow‐up for C‐reactive protein (<italic>P</italic>=0.77), interleukin‐6 (<italic>P</italic>=0.91), intercellular adhesion molecule 1 (<italic>P</italic>=0.38), or fibrinogen (<italic>P</italic>=0.68).</p>
                </sec>
                <sec id="jah33201-sec-0003">
                  <title>Conclusions</title>
                  <p>These findings indicate that long‐term, combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> lowers homocysteine concentrations, but does not alter major biomarkers of vascular inflammation, consistent with the lack of clinical cardiovascular disease benefit in the trial.</p>
                </sec>
                <sec id="jah33201-sec-0004">
                  <title>Clinical Trial Registration</title>
                  <p><styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00000541.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah33201-kwd-0001">B vitamins</kwd>
                <kwd id="jah33201-kwd-0002">biomarkers</kwd>
                <kwd id="jah33201-kwd-0003">cardiovascular disease</kwd>
                <kwd id="jah33201-kwd-0004">endothelial dysfunction</kwd>
                <kwd id="jah33201-kwd-0005">inflammation</kwd>
                <kwd id="jah33201-kwd-0006">randomized trial</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Cardiovascular Disease</kwd>
                <kwd>Secondary Prevention</kwd>
                <kwd>Diet and Nutrition</kwd>
                <kwd>Women</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>National Heart, Lung, and Blood Institute</funding-source>
                  <award-id>HL46959</award-id>
                </award-group>
                <award-group>
                  <funding-source>National Eye Institute</funding-source>
                  <award-id>EY06633</award-id>
                  <award-id>EY18820</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="0"/>
                <table-count count="5"/>
                <page-count count="9"/>
                <word-count count="7248"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>jah33201</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>05 June 2018</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.0 mode:remove_FC converted:05.06.2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah33201-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>:<elocation-id>e008517</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.008517">10.1161/JAHA.117.008517</ext-link>.)<pub-id pub-id-type="pmid">29776960</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah33201-blkfxd-0001" orientation="portrait">
                <sec id="jah33201-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah33201-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah33201-list-0001">
                        <list-item>
                          <p>Our substudy findings from a large, randomized trial of women at increased risk of cardiovascular disease indicate that combined treatment with B vitamins for treatment durations as long as 7.3 years has no effect on plasma biomarkers of inflammation and endothelial function, despite a significant reduction in homocysteine concentration.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah33201-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah33201-list-0002">
                        <list-item>
                          <p>These findings may partly explain the absence of clinical benefit for homocysteine lowering in secondary prevention trials of cardiovascular disease.</p>
                        </list-item>
                        <list-item>
                          <p>These findings also suggest that mildly or moderately elevated homocysteine may not be an important causal factor in vascular inflammation in patients at high risk for cardiovascular disease.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah33201-sec-0009">
              <p>Mild or moderate hyperhomocysteinemia, typically defined as fasting blood homocysteine concentrations between 12 and 30 μmol/L,<xref rid="jah33201-bib-0001" ref-type="ref">1</xref>, <xref rid="jah33201-bib-0002" ref-type="ref">2</xref> has been associated with increased risks of cardiovascular disease (CVD) in observational studies.<xref rid="jah33201-bib-0003" ref-type="ref">3</xref> However, evidence supporting a causal relationship is lacking. In vitro studies and studies in animals and humans show that mildly or moderately elevated homocysteine is associated with several important components of atherogenesis, including vascular inflammation, endothelial dysfunction, and hypercoagulability<xref rid="jah33201-bib-0004" ref-type="ref">4</xref>; however, the extent to which these and other pathogenic mechanisms may underlie the apparent association with CVD remains unclear.</p>
              <p>The WAFACS (Women's Antioxidant and Folic Acid Cardiovascular Study), conducted among women at high CVD risk, showed that combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> for 7.3 years significantly reduced homocysteine concentrations, but did not reduce a combined end point of total cardiovascular events.<xref rid="jah33201-bib-0005" ref-type="ref">5</xref> Meta‐analyses of other randomized trials in high‐risk patients similarly indicate that homocysteine lowering with B vitamins has no beneficial effect on CVD or venous thrombosis, although a possible benefit on stroke has been suggested.<xref rid="jah33201-bib-0006" ref-type="ref">6</xref>, <xref rid="jah33201-bib-0007" ref-type="ref">7</xref>, <xref rid="jah33201-bib-0008" ref-type="ref">8</xref>, <xref rid="jah33201-bib-0009" ref-type="ref">9</xref>, <xref rid="jah33201-bib-0010" ref-type="ref">10</xref> One interpretation of the mostly null findings in trials is that elevated homocysteine is a marker of suboptimal B‐vitamin status, but is not causally related to CVD. Others have speculated that the beneficial effects of homocysteine lowering may be countered by adverse effects of high‐dose B vitamins such as an increase in inflammation or endothelial dysfunction.<xref rid="jah33201-bib-0011" ref-type="ref">11</xref>, <xref rid="jah33201-bib-0012" ref-type="ref">12</xref> With regard to this possibility, current evidence, including substudies of randomized trials, suggests that homocysteine lowering with B vitamins has little impact on plasma biomarkers of inflammation<xref rid="jah33201-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33201-bib-0013" ref-type="ref">13</xref>, <xref rid="jah33201-bib-0014" ref-type="ref">14</xref>, <xref rid="jah33201-bib-0015" ref-type="ref">15</xref>, <xref rid="jah33201-bib-0016" ref-type="ref">16</xref>, <xref rid="jah33201-bib-0017" ref-type="ref">17</xref>, <xref rid="jah33201-bib-0018" ref-type="ref">18</xref>, <xref rid="jah33201-bib-0019" ref-type="ref">19</xref>, <xref rid="jah33201-bib-0020" ref-type="ref">20</xref>, <xref rid="jah33201-bib-0021" ref-type="ref">21</xref>, <xref rid="jah33201-bib-0022" ref-type="ref">22</xref>, <xref rid="jah33201-bib-0023" ref-type="ref">23</xref>, <xref rid="jah33201-bib-0024" ref-type="ref">24</xref>, <xref rid="jah33201-bib-0025" ref-type="ref">25</xref>, <xref rid="jah33201-bib-0026" ref-type="ref">26</xref>, <xref rid="jah33201-bib-0027" ref-type="ref">27</xref> and endothelial dysfunction.<xref rid="jah33201-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33201-bib-0017" ref-type="ref">17</xref>, <xref rid="jah33201-bib-0018" ref-type="ref">18</xref>, <xref rid="jah33201-bib-0024" ref-type="ref">24</xref>, <xref rid="jah33201-bib-0028" ref-type="ref">28</xref>, <xref rid="jah33201-bib-0029" ref-type="ref">29</xref> However, most of these studies have been limited by small sample size (n&lt;200) and short treatment duration (&lt;2 years).</p>
              <p>To address this question, we investigated the effect of long‐term, combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> on plasma biomarkers of chronic inflammation and endothelial dysfunction in a subsample of 300 participants in WAFACS.<xref rid="jah33201-bib-0005" ref-type="ref">5</xref>
</p>
            </sec>
            <sec id="jah33201-sec-0010">
              <title>Methods</title>
              <p>The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.</p>
              <sec id="jah33201-sec-0011">
                <title>Study Population</title>
                <p>The WAFACS was a randomized, double‐blind, placebo‐controlled trial that evaluated whether a daily combination of folic acid (2.5 mg), vitamin B<sub>6</sub> (50 mg), and vitamin B<sub>12</sub> (1 mg) could reduce cardiovascular events among women with pre‐existing CVD or 3 or more coronary risk factors. The WAFACS trial began in 1998 when the folic acid/B<sub>6</sub>/B<sub>12</sub> arm was added to the ongoing WACS (Women's Antioxidant Cardiovascular Study). The WACS was a 2×2×2 factorial trial of 8171 women at high risk of CVD randomized between June 1995 and October 1996 to high‐dose antioxidants (vitamin E, vitamin C, and beta carotene) or placebo. In April, 1998, 5442 of the 8171 WACS participants who were willing and eligible for participation in the new arm of the trial were further randomized to folic acid/B<sub>6</sub>/B<sub>12</sub> or placebo in a retained factorial design. Randomized treatment in the WAFACS ended on July 31, 2005 for a mean treatment duration of 7.3 years. Details of the overall trial design and the main results from the WAFACS and WACS have been reported previously.<xref rid="jah33201-bib-0005" ref-type="ref">5</xref>, <xref rid="jah33201-bib-0030" ref-type="ref">30</xref>, <xref rid="jah33201-bib-0031" ref-type="ref">31</xref> The trial was approved by the institutional review board of the Brigham and Women's Hospital (Boston, MA), and all patients provided written informed consent.</p>
              </sec>
              <sec id="jah33201-sec-0012">
                <title>Blood Substudy</title>
                <p>A total of 2596 women in the WAFACS provided a baseline blood sample at study entry in 1996, preceding the initiation of background dietary folic acid fortification of the US food supply in 1998. From this group, 300 randomly selected participants who were adherent with study medications (150 in the active treatment group, 150 in the placebo group) provided a follow‐up blood sample at the end of randomized treatment.</p>
              </sec>
              <sec id="jah33201-sec-0013">
                <title>Blood Collection and Storage</title>
                <p>Similar kits and procedures were used for baseline and follow‐up blood collections in this preplanned substudy. Women were mailed a blood collection kit that contained instructions, three 10‐mL EDTA vacutainer tubes, three 4.5‐mL sodium citrate tubes, supplies needed to draw a sample of blood, a completed overnight courier air bill, and a gel‐filled freezer pack. Women were asked to freeze the gel‐filled freezer pack to serve as a coolant for mailing. The next day, they had a blood sample drawn into 2 EDTA and 2 citrate tubes and returned the completed kit by overnight courier. All samples arrived in our laboratory within 24 to 30 hours of venipuncture, were kept chilled until processed, and were stored at −120 to −160°C within 30 to 36 hours of venipuncture.</p>
              </sec>
              <sec id="jah33201-sec-0014">
                <title>Measurement of Plasma Biomarkers</title>
                <sec id="jah33201-sec-0015">
                  <title>High‐sensitivity C‐reactive protein</title>
                  <p>The concentration of CRP (C‐reactive protein) was determined using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN), using reagents and calibrators from DiaSorin (Stillwater, MN). This assay has a sensitivity of 0.03 mg/L. Interassay coefficients of variation (CVs) at concentrations of 0.91, 3.07, and 13.38 mg/L are 2.81%, 1.61%, and 1.1%, respectively.</p>
                </sec>
                <sec id="jah33201-sec-0016">
                  <title>Interleukin‐6</title>
                  <p>Interleukin (IL‐6) was measured by an ultrasensitive ELISA assay from R &amp; D Systems (Minneapolis, MN) using the quantitative sandwich enzyme immunoassay technique. The assay has a sensitivity of 0.094 pg/mL, and interassay CVs at concentrations of 0.49, 2.78, and 5.65 pg/mL are 9.6%, 7.2%, and 6.5%, respectively.</p>
                </sec>
                <sec id="jah33201-sec-0017">
                  <title>Intracellular adhesion molecule‐1</title>
                  <p>Intracellular adhesion molecule‐1 (ICAM‐1) was measured by an ELISA assay (R &amp; D Systems) using the quantitative sandwich enzyme immunoassay technique. The assay has a sensitivity of 0.35 ng/mL, and interassay CVs at concentrations of 64.2, 117, 290, and 453 ng/mL are 10.1%, 7.4%, 6.0%, and 6.1%, respectively.</p>
                </sec>
                <sec id="jah33201-sec-0018">
                  <title>Fibrinogen</title>
                  <p>Concentration of fibrinogen was determined using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics), using reagents and calibrators from Kamiya Biomedical Co. Interassay CVs at concentrations of 167.4, 323.6, and 554.1 mg/dL are 0.94%, 1.06%, and 1.50%, respectively.</p>
                </sec>
                <sec id="jah33201-sec-0019">
                  <title>Folate</title>
                  <p>Concentration of folate was determined by a chemiluminescence method using the 2010 Elecsys utoimmunoanalyzer (Roche Diagnostics, Basel, Switzerland). Interassay CV ranges from 1.9% to 7.7% depending on plasma level.</p>
                </sec>
                <sec id="jah33201-sec-0020">
                  <title>Homocysteine</title>
                  <p>Concentration of homocysteine was determined using an enzymatic assay on the Hitachi 917 analyzer (Roche Diagnostics), using reagents and calibrators from Catch Inc. (Seattle, WA). Interassay CV ranges from 3.9% to 7.5% depending on plasma level.</p>
                </sec>
              </sec>
              <sec id="jah33201-sec-0021">
                <title>Statistical Analyses</title>
                <p>Baseline demographic and lifestyle characteristics in the 2 randomized treatment groups were compared using the Student <italic>t</italic> test for continuous variables expressed as means (SD) and chi‐square tests for categorical data. Raw distributions and median values (interquartile range) of biomarkers at baseline were compared using the nonparametric Wilcoxon rank‐sum test. Spearman correlation coefficients were used to examine the inter‐relation of biomarkers in the combined sample at baseline.</p>
                <p>We examined the effect of folic acid fortification in the United States in 1998 by determining the change in biomarker concentrations from baseline to follow‐up in the placebo group. For folate, we compared the raw distributions and median values at baseline and follow‐up using the nonparametric Wilcoxon signed‐rank test. For homocysteine, CRP, ICAM‐1, IL‐6, and fibrinogen, we compared geometric means after natural logarithmic transformation at baseline and follow‐up using the paired <italic>t</italic> test.</p>
                <p>To assess the effect of treatment on plasma biomarkers, we compared the change from baseline to follow‐up in both the active and placebo groups. For folate, we compared the change in ordinal categories in the active and placebo group using a repeated‐measures cumulative logit model in PROC GENMOD of SAS. For homocysteine, CRP, ICAM‐1, IL‐6, and fibrinogen, we compared the change observed in the active group over the placebo group by computing the difference between groups in the change in the natural logarithm of biomarker concentration from baseline to follow‐up.</p>
                <p>Finally, because hormone replacement therapy (HRT) has been shown to increase plasma CRP concentrations, but reduce concentrations of all other biomarkers of vascular inflammation,<xref rid="jah33201-bib-0032" ref-type="ref">32</xref>, <xref rid="jah33201-bib-0033" ref-type="ref">33</xref> we examined the association at baseline of current HRT use and biomarker concentration, and whether change in concentration at the end of follow‐up was associated with change in HRT use during follow‐up.</p>
              </sec>
            </sec>
            <sec id="jah33201-sec-0022">
              <title>Results</title>
              <p>Table <xref rid="jah33201-tbl-0001" ref-type="table">1</xref> displays the baseline characteristics of the 300 adherent participants in the blood substudy according to treatment group. Participants were similar with respect to all characteristics listed in the table except for history of diabetes mellitus (21.3% in the active treatment group versus 12.0% in the placebo group; <italic>P</italic>=0.03). Median plasma biomarker concentrations were similar in the active treatment and placebo groups at baseline (all <italic>P</italic>≥0.20).</p>
              <table-wrap id="jah33201-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics According to Randomized Treatment Assignment</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1"/>
                      <th align="left" valign="top" rowspan="1" colspan="1">Folic Acid/B<sub>6</sub>/B<sub>12</sub> (n=150)</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">Placebo (n=150)</th>
                      <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Age (mean [SD] y)</td>
                      <td align="left" rowspan="1" colspan="1">62.1 (8.2)</td>
                      <td align="left" rowspan="1" colspan="1">62.1 (8.6)</td>
                      <td align="left" rowspan="1" colspan="1">0.94</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Cigarette smoking, %</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">0.65</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Never</td>
                      <td align="left" rowspan="1" colspan="1">55.3</td>
                      <td align="left" rowspan="1" colspan="1">50.0</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Former</td>
                      <td align="left" rowspan="1" colspan="1">37.3</td>
                      <td align="left" rowspan="1" colspan="1">41.3</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Current</td>
                      <td align="left" rowspan="1" colspan="1">7.3</td>
                      <td align="left" rowspan="1" colspan="1">8.7</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Alcohol use, %</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1">0.49</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Rarely/never</td>
                      <td align="left" rowspan="1" colspan="1">52.7</td>
                      <td align="left" rowspan="1" colspan="1">48.7</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> ≥1 drink/month</td>
                      <td align="left" rowspan="1" colspan="1">47.3</td>
                      <td align="left" rowspan="1" colspan="1">51.3</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">BMI (mean [SD], kg/m<sup>2</sup>)</td>
                      <td align="left" rowspan="1" colspan="1">30.7 (6.2)</td>
                      <td align="left" rowspan="1" colspan="1">30.1 (6.3)</td>
                      <td align="left" rowspan="1" colspan="1">0.44</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Exercise ≥1 time/week, %</td>
                      <td align="left" rowspan="1" colspan="1">47.3</td>
                      <td align="left" rowspan="1" colspan="1">36.7</td>
                      <td align="left" rowspan="1" colspan="1">0.06</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="4" rowspan="1">Reported history</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Hypertension<xref ref-type="fn" rid="jah33201-note-0002">a</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">86.0</td>
                      <td align="left" rowspan="1" colspan="1">88.0</td>
                      <td align="left" rowspan="1" colspan="1">0.61</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> High cholesterol<xref ref-type="fn" rid="jah33201-note-0003">b</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">76.0</td>
                      <td align="left" rowspan="1" colspan="1">81.3</td>
                      <td align="left" rowspan="1" colspan="1">0.26</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Diabetes mellitus</td>
                      <td align="left" rowspan="1" colspan="1">21.3</td>
                      <td align="left" rowspan="1" colspan="1">12.0</td>
                      <td align="left" rowspan="1" colspan="1">0.03</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1"> CVD</td>
                      <td align="left" rowspan="1" colspan="1">65.3</td>
                      <td align="left" rowspan="1" colspan="1">56.7</td>
                      <td align="left" rowspan="1" colspan="1">0.12</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Aspirin use<xref ref-type="fn" rid="jah33201-note-0004">c</xref>, %</td>
                      <td align="left" rowspan="1" colspan="1">54.7</td>
                      <td align="left" rowspan="1" colspan="1">48.7</td>
                      <td align="left" rowspan="1" colspan="1">0.30</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">HRT, %</td>
                      <td align="left" rowspan="1" colspan="1">54.0</td>
                      <td align="left" rowspan="1" colspan="1">54.7</td>
                      <td align="left" rowspan="1" colspan="1">0.91</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Current multivitamin use<xref ref-type="fn" rid="jah33201-note-0005">d</xref>, %</td>
                      <td align="left" rowspan="1" colspan="1">20.0</td>
                      <td align="left" rowspan="1" colspan="1">24.0</td>
                      <td align="left" rowspan="1" colspan="1">0.40</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Randomized to vitamin E</td>
                      <td align="left" rowspan="1" colspan="1">44.7</td>
                      <td align="left" rowspan="1" colspan="1">48.7</td>
                      <td align="left" rowspan="1" colspan="1">0.49</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Randomized to vitamin C</td>
                      <td align="left" rowspan="1" colspan="1">52.7</td>
                      <td align="left" rowspan="1" colspan="1">45.3</td>
                      <td align="left" rowspan="1" colspan="1">0.20</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Randomized to beta carotene</td>
                      <td align="left" rowspan="1" colspan="1">57.3</td>
                      <td align="left" rowspan="1" colspan="1">55.3</td>
                      <td align="left" rowspan="1" colspan="1">0.73</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Folate (median [IQR], ng/mL)</td>
                      <td align="left" rowspan="1" colspan="1">8.8 (6.4–12.8)</td>
                      <td align="left" rowspan="1" colspan="1">8.9 (6.0–13.4)</td>
                      <td align="left" rowspan="1" colspan="1">0.94</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Homocysteine (median [IQR], μmol/L)</td>
                      <td align="left" rowspan="1" colspan="1">12.1 (10.2–15.0)</td>
                      <td align="left" rowspan="1" colspan="1">12.5 (9.6–15.5)</td>
                      <td align="left" rowspan="1" colspan="1">0.96</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">hsCRP (median [IQR], mg/L)</td>
                      <td align="left" rowspan="1" colspan="1">3.8 (1.8–7.4)</td>
                      <td align="left" rowspan="1" colspan="1">4.7 (1.9–8.7)</td>
                      <td align="left" rowspan="1" colspan="1">0.32</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">ICAM‐1 (median [IQR], ng/mL)</td>
                      <td align="left" rowspan="1" colspan="1">260.1 (228.9–298.6)</td>
                      <td align="left" rowspan="1" colspan="1">268.4 (232.5–304.4)</td>
                      <td align="left" rowspan="1" colspan="1">0.57</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">IL‐6 (median [IQR], pg/mL)</td>
                      <td align="left" rowspan="1" colspan="1">1.4 (0.9–1.9)</td>
                      <td align="left" rowspan="1" colspan="1">1.5 (1.1–2.2)</td>
                      <td align="left" rowspan="1" colspan="1">0.20</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Fibrinogen (median [IQR], mg/dL)</td>
                      <td align="left" rowspan="1" colspan="1">486.4 (426.8–557.5)</td>
                      <td align="left" rowspan="1" colspan="1">501.1 (441.0–583.5)</td>
                      <td align="left" rowspan="1" colspan="1">0.22</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="jah33201-note-0001">
                    <p>BMI indicates body mass index; CVD, cardiovascular disease; HRT, hormone replacement therapy; hsCRP, high‐sensitivity C‐reactive protein; ICAM‐1, intracellular adhesion molecule‐1; IL‐6, interleukin‐6; IQR, interquartile range; WAFACS, Women's Antioxidant and Folic Acid Cardiovascular Study.</p>
                  </fn>
                  <fn id="jah33201-note-0002">
                    <label>a</label>
                    <p>Self‐reported systolic blood pressure &gt;140 mm Hg, diastolic blood pressure &gt;90 mm Hg; self‐reported physician‐diagnosed hypertension; or reported treatment with medication for hypertension.</p>
                  </fn>
                  <fn id="jah33201-note-0003">
                    <label>b</label>
                    <p>Self‐reported high cholesterol, cholesterol level &gt;240 mg/dL; self‐reported physician diagnosed, high cholesterol levels; or reported treatment with cholesterol‐lowering medication.</p>
                  </fn>
                  <fn id="jah33201-note-0004">
                    <label>c</label>
                    <p>Aspirin use at least 4 times per month.</p>
                  </fn>
                  <fn id="jah33201-note-0005">
                    <label>d</label>
                    <p>Any multivitamin use in the past month.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="jah33201-sec-0023">
                <title>Correlation Among Biomarkers at Baseline</title>
                <p>Results of correlational analyses of the combined sample at baseline are presented in Table <xref rid="jah33201-tbl-0002" ref-type="table">2</xref>. Plasma folate showed a significant inverse correlation with homocysteine (ρ=−0.29; <italic>P</italic>&lt;0.0001) and weaker inverse correlations with IL‐6 (ρ=−0.16; <italic>P</italic>&lt;0.01), fibrinogen (ρ=−0.13; <italic>P</italic>&lt;0.05), and ICAM‐1 (ρ=−0.12; <italic>P</italic>&lt;0.05). Homocysteine was weakly correlated with ICAM‐1 and fibrinogen (both ρ=0.16; <italic>P</italic>&lt;0.01), but not with IL‐6 or CRP. IL‐6, ICAM‐1, fibrinogen, and CRP were all positively intercorrelated (ranging from ρ=0.28 to 0.42; all <italic>P</italic>&lt;0.0001).</p>
                <table-wrap id="jah33201-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Spearman Correlation Matrix for Baseline Plasma Concentrations of Folate, Homocysteine, and Biomarkers of Inflammation and Endothelial Dysfunction Among Blood Substudy Participants in WAFACS (n=300)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Folate</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Homocysteine</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">CRP</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">ICAM‐1</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">IL‐6</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Fibrinogen</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Folate</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Homocysteine</td>
                        <td align="left" rowspan="1" colspan="1">−0.29<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CRP</td>
                        <td align="left" rowspan="1" colspan="1">−0.11</td>
                        <td align="left" rowspan="1" colspan="1">−0.09</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ICAM‐1</td>
                        <td align="left" rowspan="1" colspan="1">−0.12<xref ref-type="fn" rid="jah33201-note-0007">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.16<xref ref-type="fn" rid="jah33201-note-0008">c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.29<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IL‐6</td>
                        <td align="left" rowspan="1" colspan="1">−0.16<xref ref-type="fn" rid="jah33201-note-0008">c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.10</td>
                        <td align="left" rowspan="1" colspan="1">0.41<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.39<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fibrinogen</td>
                        <td align="left" rowspan="1" colspan="1">−0.13<xref ref-type="fn" rid="jah33201-note-0007">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.16<xref ref-type="fn" rid="jah33201-note-0008">c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.42<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.28<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.39<xref ref-type="fn" rid="jah33201-note-0006">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33201-note-0100">
                      <p>CRP indicates C‐reactive protein; ICAM‐1, intracellular adhesion molecule‐1; IL‐6, interleukin‐6; WAFACS, Women's Antioxidant and Folic Acid Cardiovascular Study.</p>
                    </fn>
                    <fn id="jah33201-note-0006">
                      <label>a</label>
                      <p><italic>P</italic>&lt;0.0001.</p>
                    </fn>
                    <fn id="jah33201-note-0007">
                      <label>b</label>
                      <p><italic>P</italic>&lt;0.05.</p>
                    </fn>
                    <fn id="jah33201-note-0008">
                      <label>c</label>
                      <p><italic>P</italic>&lt;0.01.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah33201-sec-0024">
                <title>Effect of Combination Treatment With Folic Acid, Vitamin B<sub>6</sub>, and Vitamin B<sub>12</sub> on Biomarkers</title>
                <sec id="jah33201-sec-0025">
                  <title>Folate and homocysteine</title>
                  <p>Table <xref rid="jah33201-tbl-0003" ref-type="table">3</xref> displays the distribution of folate concentrations at baseline and follow‐up for 150 participants in the placebo group and 150 participants in the active group. At baseline, before the initiation of fortification, folate concentrations were similar in the active treatment group and placebo group (median, 8.8  versus 8.9 ng/mL, respectively; <italic>P</italic>=0.94, data in Table <xref rid="jah33201-tbl-0001" ref-type="table">1</xref>), with approximately one third of participants in each group having concentrations considered inadequate (&lt;7 ng/mL). At the end of study follow‐up, median folate concentration increased significantly in the placebo group to 15.4 ng/mL (interquartile range, 11.5–22.6 ng/mL; <italic>P</italic>&lt;0.001); however, the relative increase in folate concentration was greater in the active treatment group, in which 49.3% of participants had a folate concentration greater than 40 ng/mL (the upper limit of the assay) as compared with 4.7% in the placebo group (<italic>P</italic>&lt;0.001).</p>
                  <table-wrap id="jah33201-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 3</label>
                    <caption>
                      <p>Distribution of Plasma Folate Concentrations at Baseline and End of Treatment and Follow‐Up Among Blood Substudy Participants in WAFACS</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="2" valign="top" colspan="1">Folate, ng/mL</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline, N (%)</th>
                          <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Follow‐up, N (%)</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">Placebo (n=150)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Folic Acid/B<sub>6</sub>/B<sub>12</sub> (n=150)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Placebo (n=150)</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Folic Acid/B<sub>6</sub>/B<sub>12</sub> (n=150)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">&lt;7</td>
                          <td align="left" rowspan="1" colspan="1">52 (34.7)</td>
                          <td align="left" rowspan="1" colspan="1">49 (32.7)</td>
                          <td align="left" rowspan="1" colspan="1">2 (1.33)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">7 to &lt;15</td>
                          <td align="left" rowspan="1" colspan="1">71 (47.3)</td>
                          <td align="left" rowspan="1" colspan="1">80 (53.3)</td>
                          <td align="left" rowspan="1" colspan="1">69 (46.0)</td>
                          <td align="left" rowspan="1" colspan="1">1 (0.67)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">15 to &lt;25</td>
                          <td align="left" rowspan="1" colspan="1">22 (14.7)</td>
                          <td align="left" rowspan="1" colspan="1">19 (12.7)</td>
                          <td align="left" rowspan="1" colspan="1">54 (36.0)</td>
                          <td align="left" rowspan="1" colspan="1">21 (14.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">25 to 40</td>
                          <td align="left" rowspan="1" colspan="1">4 (2.67)</td>
                          <td align="left" rowspan="1" colspan="1">2 (1.33)</td>
                          <td align="left" rowspan="1" colspan="1">18 (12.0)</td>
                          <td align="left" rowspan="1" colspan="1">54 (36.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">&gt;40</td>
                          <td align="left" rowspan="1" colspan="1">1 (0.67)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">7 (4.67)</td>
                          <td align="left" rowspan="1" colspan="1">74 (49.3)</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah33201-note-0010">
                        <p>WAFACS indicates Women's Antioxidant and Folic Acid Cardiovascular Study.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <p>Despite the significant increase in folate concentration in the placebo group, there was no apparent reduction in homocysteine in that group at the end of the study as compared with baseline (Table <xref rid="jah33201-tbl-0004" ref-type="table">4</xref>). In the active treatment group, homocysteine at the end of the study decreased by 18.3% compared with baseline, and this change was significantly greater than the change observed in the placebo group (<italic>P</italic>&lt;0.001).</p>
                  <table-wrap id="jah33201-tbl-0004" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 4</label>
                    <caption>
                      <p>Change in Biomarker Concentrations According to Treatment Group Among Blood Substudy Participants in WAFACS</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="2" valign="top" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo (n=150)</th>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Folic Acid/B<sub>6</sub>/B<sub>12</sub> (n=150)</th>
                          <th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value<xref ref-type="fn" rid="jah33201-note-0012">b</xref>
</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Follow‐Up</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">% Change<xref ref-type="fn" rid="jah33201-note-0011">a</xref>
</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Follow‐Up</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">% Change<xref ref-type="fn" rid="jah33201-note-0011">a</xref>
</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Homocysteine (mean<xref ref-type="fn" rid="jah33201-note-0013">c</xref>, μmol/L)</td>
                          <td align="left" rowspan="1" colspan="1">12.3</td>
                          <td align="left" rowspan="1" colspan="1">12.3</td>
                          <td align="left" rowspan="1" colspan="1">0.0</td>
                          <td align="left" rowspan="1" colspan="1">0.99</td>
                          <td align="left" rowspan="1" colspan="1">12.2</td>
                          <td align="left" rowspan="1" colspan="1">10.0</td>
                          <td align="left" rowspan="1" colspan="1">−18.3</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">CRP (mean<xref ref-type="fn" rid="jah33201-note-0013">c</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">3.9</td>
                          <td align="left" rowspan="1" colspan="1">2.5</td>
                          <td align="left" rowspan="1" colspan="1">−35.4</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">3.5</td>
                          <td align="left" rowspan="1" colspan="1">2.4</td>
                          <td align="left" rowspan="1" colspan="1">−33.4</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.77</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">ICAM‐1 (mean<xref ref-type="fn" rid="jah33201-note-0013">c</xref>, ng/mL)</td>
                          <td align="left" rowspan="1" colspan="1">266.1</td>
                          <td align="left" rowspan="1" colspan="1">259.2</td>
                          <td align="left" rowspan="1" colspan="1">−2.6</td>
                          <td align="left" rowspan="1" colspan="1">0.10</td>
                          <td align="left" rowspan="1" colspan="1">266.6</td>
                          <td align="left" rowspan="1" colspan="1">265.2</td>
                          <td align="left" rowspan="1" colspan="1">−0.5</td>
                          <td align="left" rowspan="1" colspan="1">0.77</td>
                          <td align="left" rowspan="1" colspan="1">0.38</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">IL‐6 (mean<xref ref-type="fn" rid="jah33201-note-0013">c</xref>, pg/mL)</td>
                          <td align="left" rowspan="1" colspan="1">1.5</td>
                          <td align="left" rowspan="1" colspan="1">1.8</td>
                          <td align="left" rowspan="1" colspan="1">23.8</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">1.4</td>
                          <td align="left" rowspan="1" colspan="1">1.7</td>
                          <td align="left" rowspan="1" colspan="1">22.5</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.91</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Fibrinogen (mean<xref ref-type="fn" rid="jah33201-note-0013">c</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">501.7</td>
                          <td align="left" rowspan="1" colspan="1">519.0</td>
                          <td align="left" rowspan="1" colspan="1">3.5</td>
                          <td align="left" rowspan="1" colspan="1">0.053</td>
                          <td align="left" rowspan="1" colspan="1">486.9</td>
                          <td align="left" rowspan="1" colspan="1">508.3</td>
                          <td align="left" rowspan="1" colspan="1">4.4</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.68</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah33201-note-0111">
                        <p>CRP indicates C‐reactive protein; ICAM‐1, intracellular adhesion molecule‐1; IL‐6, interleukin‐6; WAFACS, Women's Antioxidant and Folic Acid Cardiovascular Study.</p>
                      </fn>
                      <fn id="jah33201-note-0011">
                        <label>a</label>
                        <p>Percent change in group mean.</p>
                      </fn>
                      <fn id="jah33201-note-0012">
                        <label>b</label>
                        <p><italic>P</italic> value for difference in change in geometric mean from baseline to follow‐up comparing treated and placebo groups.</p>
                      </fn>
                      <fn id="jah33201-note-0013">
                        <label>c</label>
                        <p>Geometric mean.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="jah33201-sec-0026">
                  <title>CRP, IL‐6, ICAM‐1, and fibrinogen</title>
                  <p>As shown in Table <xref rid="jah33201-tbl-0004" ref-type="table">4</xref>, CRP concentrations in the placebo group decreased significantly (<italic>P</italic>&lt;0.001) from baseline, whereas IL‐6 increased significantly (<italic>P</italic>&lt;0.001). ICAM‐1 and fibrinogen at follow‐up were not significantly different from baseline in the placebo group. For all 4 biomarkers, the changes observed in the active treatment group closely mirrored those in the placebo group, and there was no significant difference between treatment groups in change from baseline for any biomarker.</p>
                  <p>We examined whether the significant changes in CRP and IL‐6 in both treatment groups were related to change in use of HRT during follow‐up. At baseline, 163 participants reported current use of HRT. These participants had higher CRP concentrations (<italic>P</italic>&lt;0.001) and lower concentrations of fibrinogen (<italic>P</italic>&lt;0.001) and homocysteine (<italic>P</italic>&lt;0.001) than did HRT nonusers (data not shown). During follow‐up, 136 of the 163 HRT users discontinued use. As shown in Table <xref rid="jah33201-tbl-0005" ref-type="table">5</xref>, participants who discontinued HRT use during follow‐up (ie, switchers) experienced a significant decrease in CRP concentration in both the placebo and active group. Participants who maintained HRT use during follow‐up (ie, nonswitchers) experienced no change in CRP. For IL‐6 and the other biomarkers, there was no clear relation between change in HRT use during follow‐up and change in biomarker concentrations at the end of follow‐up.</p>
                  <table-wrap id="jah33201-tbl-0005" xml:lang="en" orientation="portrait" position="float">
                    <label>Table 5</label>
                    <caption>
                      <p>Change in Biomarker Concentrations According to Treatment Group Among 163 HRT Users at Baseline (136 Switchers vs 27 Nonswitchers) and 137 HRT Nonusers at Baseline (45 Switchers vs 92 Nonswitchers) Among Blood Substudy Participants in WAFACS</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <col style="border-right:solid 1px #000000" span="1"/>
                      <thead valign="top">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" rowspan="2" valign="top" colspan="1"/>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th>
                          <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Folic Acid/B<sub>6</sub>/B<sub>12</sub>
</th>
                          <th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value<xref ref-type="fn" rid="jah33201-note-0015">a</xref>
</th>
                        </tr>
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Follow‐Up</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">% Change</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Baseline</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">Follow‐Up</th>
                          <th align="left" valign="top" rowspan="1" colspan="1">% Change</th>
                          <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="10" rowspan="1">HRT users at baseline (n=163)</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nonswitchers</td>
                          <td align="left" colspan="4" rowspan="1">(n=10)</td>
                          <td align="left" colspan="4" rowspan="1">(n=17)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Homocysteine (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, μmol/L)</td>
                          <td align="left" rowspan="1" colspan="1">10.68</td>
                          <td align="left" rowspan="1" colspan="1">11.17</td>
                          <td align="left" rowspan="1" colspan="1">4.6</td>
                          <td align="left" rowspan="1" colspan="1">0.80</td>
                          <td align="left" rowspan="1" colspan="1">12.33</td>
                          <td align="left" rowspan="1" colspan="1">9.15</td>
                          <td align="left" rowspan="1" colspan="1">−25.8</td>
                          <td align="left" rowspan="1" colspan="1">0.002</td>
                          <td align="left" rowspan="1" colspan="1">0.048</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CRP (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">3.94</td>
                          <td align="left" rowspan="1" colspan="1">3.70</td>
                          <td align="left" rowspan="1" colspan="1">−6.2</td>
                          <td align="left" rowspan="1" colspan="1">0.82</td>
                          <td align="left" rowspan="1" colspan="1">3.06</td>
                          <td align="left" rowspan="1" colspan="1">2.66</td>
                          <td align="left" rowspan="1" colspan="1">−12.9</td>
                          <td align="left" rowspan="1" colspan="1">0.46</td>
                          <td align="left" rowspan="1" colspan="1">0.82</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">ICAM‐1 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, ng/mL)</td>
                          <td align="left" rowspan="1" colspan="1">237.37</td>
                          <td align="left" rowspan="1" colspan="1">233.13</td>
                          <td align="left" rowspan="1" colspan="1">−1.8</td>
                          <td align="left" rowspan="1" colspan="1">0.73</td>
                          <td align="left" rowspan="1" colspan="1">245.85</td>
                          <td align="left" rowspan="1" colspan="1">225.18</td>
                          <td align="left" rowspan="1" colspan="1">−8.4</td>
                          <td align="left" rowspan="1" colspan="1">0.04</td>
                          <td align="left" rowspan="1" colspan="1">0.29</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">IL‐6 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, pg/mL)</td>
                          <td align="left" rowspan="1" colspan="1">1.19</td>
                          <td align="left" rowspan="1" colspan="1">1.77</td>
                          <td align="left" rowspan="1" colspan="1">49.5</td>
                          <td align="left" rowspan="1" colspan="1">0.003</td>
                          <td align="left" rowspan="1" colspan="1">1.03</td>
                          <td align="left" rowspan="1" colspan="1">1.32</td>
                          <td align="left" rowspan="1" colspan="1">28.6</td>
                          <td align="left" rowspan="1" colspan="1">0.10</td>
                          <td align="left" rowspan="1" colspan="1">0.47</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fibrinogen (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">494.61</td>
                          <td align="left" rowspan="1" colspan="1">510.04</td>
                          <td align="left" rowspan="1" colspan="1">3.1</td>
                          <td align="left" rowspan="1" colspan="1">0.67</td>
                          <td align="left" rowspan="1" colspan="1">411.14</td>
                          <td align="left" rowspan="1" colspan="1">428.25</td>
                          <td align="left" rowspan="1" colspan="1">4.2</td>
                          <td align="left" rowspan="1" colspan="1">0.16</td>
                          <td align="left" rowspan="1" colspan="1">0.89</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Switchers</td>
                          <td align="left" colspan="4" rowspan="1">(n=72)</td>
                          <td align="left" colspan="4" rowspan="1">(n=64)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Homocysteine (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, μmol/L)</td>
                          <td align="left" rowspan="1" colspan="1">11.36</td>
                          <td align="left" rowspan="1" colspan="1">12.00</td>
                          <td align="left" rowspan="1" colspan="1">5.7</td>
                          <td align="left" rowspan="1" colspan="1">0.17</td>
                          <td align="left" rowspan="1" colspan="1">11.64</td>
                          <td align="left" rowspan="1" colspan="1">10.21</td>
                          <td align="left" rowspan="1" colspan="1">−12.3</td>
                          <td align="left" rowspan="1" colspan="1">0.004</td>
                          <td align="left" rowspan="1" colspan="1">0.002</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CRP (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">5.44</td>
                          <td align="left" rowspan="1" colspan="1">2.40</td>
                          <td align="left" rowspan="1" colspan="1">−55.8</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">4.25</td>
                          <td align="left" rowspan="1" colspan="1">2.29</td>
                          <td align="left" rowspan="1" colspan="1">−46.0</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.17</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">ICAM‐1 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, ng/mL)</td>
                          <td align="left" rowspan="1" colspan="1">268.68</td>
                          <td align="left" rowspan="1" colspan="1">261.54</td>
                          <td align="left" rowspan="1" colspan="1">−2.7</td>
                          <td align="left" rowspan="1" colspan="1">0.29</td>
                          <td align="left" rowspan="1" colspan="1">271.59</td>
                          <td align="left" rowspan="1" colspan="1">277.80</td>
                          <td align="left" rowspan="1" colspan="1">2.3</td>
                          <td align="left" rowspan="1" colspan="1">0.43</td>
                          <td align="left" rowspan="1" colspan="1">0.19</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">IL‐6 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, pg/mL)</td>
                          <td align="left" rowspan="1" colspan="1">1.47</td>
                          <td align="left" rowspan="1" colspan="1">1.77</td>
                          <td align="left" rowspan="1" colspan="1">20.9</td>
                          <td align="left" rowspan="1" colspan="1">0.001</td>
                          <td align="left" rowspan="1" colspan="1">1.43</td>
                          <td align="left" rowspan="1" colspan="1">1.75</td>
                          <td align="left" rowspan="1" colspan="1">22.7</td>
                          <td align="left" rowspan="1" colspan="1">0.009</td>
                          <td align="left" rowspan="1" colspan="1">0.87</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fibrinogen (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">492.16</td>
                          <td align="left" rowspan="1" colspan="1">503.63</td>
                          <td align="left" rowspan="1" colspan="1">2.3</td>
                          <td align="left" rowspan="1" colspan="1">0.43</td>
                          <td align="left" rowspan="1" colspan="1">473.90</td>
                          <td align="left" rowspan="1" colspan="1">512.15</td>
                          <td align="left" rowspan="1" colspan="1">8.1</td>
                          <td align="left" rowspan="1" colspan="1">0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.12</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="10" rowspan="1">HRT nonusers at baseline (n=137)</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nonswitchers</td>
                          <td align="left" colspan="4" rowspan="1">(n=42)</td>
                          <td align="left" colspan="4" rowspan="1">(n=45)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Homocysteine (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, μmol/L)</td>
                          <td align="left" rowspan="1" colspan="1">14.81</td>
                          <td align="left" rowspan="1" colspan="1">13.30</td>
                          <td align="left" rowspan="1" colspan="1">−10.2</td>
                          <td align="left" rowspan="1" colspan="1">0.07</td>
                          <td align="left" rowspan="1" colspan="1">13.09</td>
                          <td align="left" rowspan="1" colspan="1">9.75</td>
                          <td align="left" rowspan="1" colspan="1">−25.5</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                          <td align="left" rowspan="1" colspan="1">0.02</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CRP (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">3.41</td>
                          <td align="left" rowspan="1" colspan="1">3.03</td>
                          <td align="left" rowspan="1" colspan="1">−11.3</td>
                          <td align="left" rowspan="1" colspan="1">0.50</td>
                          <td align="left" rowspan="1" colspan="1">2.99</td>
                          <td align="left" rowspan="1" colspan="1">2.22</td>
                          <td align="left" rowspan="1" colspan="1">−25.6</td>
                          <td align="left" rowspan="1" colspan="1">0.005</td>
                          <td align="left" rowspan="1" colspan="1">0.39</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">ICAM‐1 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, ng/mL)</td>
                          <td align="left" rowspan="1" colspan="1">279.62</td>
                          <td align="left" rowspan="1" colspan="1">267.03</td>
                          <td align="left" rowspan="1" colspan="1">−4.5</td>
                          <td align="left" rowspan="1" colspan="1">0.14</td>
                          <td align="left" rowspan="1" colspan="1">270.77</td>
                          <td align="left" rowspan="1" colspan="1">273.14</td>
                          <td align="left" rowspan="1" colspan="1">0.9</td>
                          <td align="left" rowspan="1" colspan="1">0.82</td>
                          <td align="left" rowspan="1" colspan="1">0.27</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">IL‐6 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, pg/mL)</td>
                          <td align="left" rowspan="1" colspan="1">1.85</td>
                          <td align="left" rowspan="1" colspan="1">2.19</td>
                          <td align="left" rowspan="1" colspan="1">18.6</td>
                          <td align="left" rowspan="1" colspan="1">0.13</td>
                          <td align="left" rowspan="1" colspan="1">1.53</td>
                          <td align="left" rowspan="1" colspan="1">1.93</td>
                          <td align="left" rowspan="1" colspan="1">26.1</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                          <td align="left" rowspan="1" colspan="1">0.66</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fibrinogen (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">536.77</td>
                          <td align="left" rowspan="1" colspan="1">549.95</td>
                          <td align="left" rowspan="1" colspan="1">2.5</td>
                          <td align="left" rowspan="1" colspan="1">0.41</td>
                          <td align="left" rowspan="1" colspan="1">522.53</td>
                          <td align="left" rowspan="1" colspan="1">537.19</td>
                          <td align="left" rowspan="1" colspan="1">2.8</td>
                          <td align="left" rowspan="1" colspan="1">0.26</td>
                          <td align="left" rowspan="1" colspan="1">0.93</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Switchers</td>
                          <td align="left" colspan="4" rowspan="1">(n=26)</td>
                          <td align="left" colspan="4" rowspan="1">(n=24)</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Homocysteine (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, μmol/L)</td>
                          <td align="left" rowspan="1" colspan="1">11.92</td>
                          <td align="left" rowspan="1" colspan="1">11.99</td>
                          <td align="left" rowspan="1" colspan="1">0.6</td>
                          <td align="left" rowspan="1" colspan="1">0.93</td>
                          <td align="left" rowspan="1" colspan="1">12.28</td>
                          <td align="left" rowspan="1" colspan="1">10.55</td>
                          <td align="left" rowspan="1" colspan="1">−14.0</td>
                          <td align="left" rowspan="1" colspan="1">0.04</td>
                          <td align="left" rowspan="1" colspan="1">0.11</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">CRP (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">2.00</td>
                          <td align="left" rowspan="1" colspan="1">1.92</td>
                          <td align="left" rowspan="1" colspan="1">−4.2</td>
                          <td align="left" rowspan="1" colspan="1">0.86</td>
                          <td align="left" rowspan="1" colspan="1">3.27</td>
                          <td align="left" rowspan="1" colspan="1">2.57</td>
                          <td align="left" rowspan="1" colspan="1">−21.4</td>
                          <td align="left" rowspan="1" colspan="1">0.18</td>
                          <td align="left" rowspan="1" colspan="1">0.51</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">ICAM‐1 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, ng/mL)</td>
                          <td align="left" rowspan="1" colspan="1">249.76</td>
                          <td align="left" rowspan="1" colspan="1">250.98</td>
                          <td align="left" rowspan="1" colspan="1">0.5</td>
                          <td align="left" rowspan="1" colspan="1">0.87</td>
                          <td align="left" rowspan="1" colspan="1">260.73</td>
                          <td align="left" rowspan="1" colspan="1">248.77</td>
                          <td align="left" rowspan="1" colspan="1">−4.6</td>
                          <td align="left" rowspan="1" colspan="1">0.06</td>
                          <td align="left" rowspan="1" colspan="1">0.17</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">IL‐6 (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, pg/mL)</td>
                          <td align="left" rowspan="1" colspan="1">1.12</td>
                          <td align="left" rowspan="1" colspan="1">1.46</td>
                          <td align="left" rowspan="1" colspan="1">29.4</td>
                          <td align="left" rowspan="1" colspan="1">0.03</td>
                          <td align="left" rowspan="1" colspan="1">1.28</td>
                          <td align="left" rowspan="1" colspan="1">1.42</td>
                          <td align="left" rowspan="1" colspan="1">11.3</td>
                          <td align="left" rowspan="1" colspan="1">0.39</td>
                          <td align="left" rowspan="1" colspan="1">0.36</td>
                        </tr>
                        <tr>
                          <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fibrinogen (mean<xref ref-type="fn" rid="jah33201-note-0016">b</xref>, mg/dL)</td>
                          <td align="left" rowspan="1" colspan="1">476.82</td>
                          <td align="left" rowspan="1" colspan="1">517.18</td>
                          <td align="left" rowspan="1" colspan="1">8.5</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                          <td align="left" rowspan="1" colspan="1">516.99</td>
                          <td align="left" rowspan="1" colspan="1">506.85</td>
                          <td align="left" rowspan="1" colspan="1">−2.0</td>
                          <td align="left" rowspan="1" colspan="1">0.44</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="jah33201-note-0014">
                        <p>CRP indicates C‐reactive protein; HRT, hormone replacement therapy; ICAM‐1, intracellular adhesion molecule‐1; IL‐6, interleukin‐6; WAFACS, Women's Antioxidant and Folic Acid Cardiovascular Study.</p>
                      </fn>
                      <fn id="jah33201-note-0015">
                        <label>a</label>
                        <p><italic>P</italic> value for difference in change in geometric mean from baseline to follow‐up comparing treated and placebo groups.</p>
                      </fn>
                      <fn id="jah33201-note-0016">
                        <label>b</label>
                        <p>Geometric mean.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
              </sec>
            </sec>
            <sec id="jah33201-sec-0027">
              <title>Discussion</title>
              <p>These findings from a substudy of adherent participants in WAFACS indicate that combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> for 7.3 years significantly reduced plasma concentrations of homocysteine, but did not alter inflammatory responses involving CRP, IL‐6, and fibrinogen or indices of endothelial dysfunction as reflected by ICAM‐1 concentration. These findings may partly explain the null results in secondary prevention trials investigating the effect of homocysteine lowering on CVD events, including the WAFACS. This suggests that mildly or moderately elevated homocysteine may not be an important causal factor in vascular inflammation in patients at high risk for CVD.</p>
              <p>Our findings for CRP, IL‐6, and fibrinogen appear consistent with the null findings for these biomarkers in other trials of homocysteine lowering conducted in selected patient groups (eg, diabetes mellitus, coronary artery disease, and peripheral artery disease). These include 4 trials with treatment duration of 1 to 2 years, all of which reported no material impact of B‐vitamin supplementation on plasma concentrations of CRP.<xref rid="jah33201-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33201-bib-0017" ref-type="ref">17</xref>, <xref rid="jah33201-bib-0019" ref-type="ref">19</xref>, <xref rid="jah33201-bib-0026" ref-type="ref">26</xref> Nine other trials examined plasma concentrations of IL‐6 or fibrinogen, and most,<xref rid="jah33201-bib-0013" ref-type="ref">13</xref>, <xref rid="jah33201-bib-0014" ref-type="ref">14</xref>, <xref rid="jah33201-bib-0016" ref-type="ref">16</xref>, <xref rid="jah33201-bib-0018" ref-type="ref">18</xref>, <xref rid="jah33201-bib-0021" ref-type="ref">21</xref>, <xref rid="jah33201-bib-0022" ref-type="ref">22</xref>, <xref rid="jah33201-bib-0023" ref-type="ref">23</xref>, <xref rid="jah33201-bib-0024" ref-type="ref">24</xref> but not all,<xref rid="jah33201-bib-0020" ref-type="ref">20</xref> found no effect of B‐vitamin supplementation on either biomarker. However, treatment duration in these trials was limited (6 months or less). Thus, our findings in WAFACS extend the previous null results for IL‐6, fibrinogen, and CRP to treatment durations as long as 7.3 years. Taken together, these findings indicate that homocysteine lowering with long‐term B vitamin treatment has no beneficial or harmful effect on plasma biomarkers of inflammation. This suggests that the association of elevated homocysteine with CVD is not likely to be explained by increased vascular inflammation.</p>
              <p>We similarly found no beneficial or harmful effect of B‐vitamin treatment on ICAM‐1. ICAM‐1 is often grouped with other inflammatory biomarkers (it is expressed on monocytes and contributes to inflammatory responses<xref rid="jah33201-bib-0034" ref-type="ref">34</xref>), but is also a biomarker of endothelial dysfunction because it mediates the adherence and passage of leukocytes across the vascular wall early in atherogenesis. Several previous trials with treatment duration of up to 2 years also found no significant effect of B‐vitamin supplementation on plasma concentration of this biomarker.<xref rid="jah33201-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33201-bib-0017" ref-type="ref">17</xref>, <xref rid="jah33201-bib-0018" ref-type="ref">18</xref>, <xref rid="jah33201-bib-0024" ref-type="ref">24</xref>, <xref rid="jah33201-bib-0028" ref-type="ref">28</xref>, <xref rid="jah33201-bib-0029" ref-type="ref">29</xref> Our present findings extend these earlier null results for ICAM‐1 to treatment durations of up to 7.3 years.</p>
              <p>Consistent with the null findings for homocysteine lowering, our cross‐sectional data at baseline also indicated little association between plasma homocysteine and the 4 biomarkers examined. These results are consistent with most,<xref rid="jah33201-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33201-bib-0014" ref-type="ref">14</xref>, <xref rid="jah33201-bib-0021" ref-type="ref">21</xref>, <xref rid="jah33201-bib-0035" ref-type="ref">35</xref>, <xref rid="jah33201-bib-0036" ref-type="ref">36</xref>, <xref rid="jah33201-bib-0037" ref-type="ref">37</xref>, <xref rid="jah33201-bib-0038" ref-type="ref">38</xref>, <xref rid="jah33201-bib-0039" ref-type="ref">39</xref> but not all,<xref rid="jah33201-bib-0040" ref-type="ref">40</xref> correlational findings for these biomarkers in other patient populations, and further support the conclusion that mildly or moderately elevated homocysteine is not an important causal factor in chronic vascular inflammation.</p>
              <p>There was an ≈2‐fold increase in plasma folate concentration, and almost complete elimination of inadequate folate concentrations (&lt;7 ng/mL), at the end of study follow‐up in the placebo group. These changes may reflect the impact of folic acid fortification of the US food supply in 1998, which was estimated to provide an additional 70 to 120 μg/day of folic acid among adults aged ≥50 years.<xref rid="jah33201-bib-0041" ref-type="ref">41</xref> Similar magnitude changes in plasma folate concentrations following fortification were observed in other populations, including the Framingham Offspring Study.<xref rid="jah33201-bib-0042" ref-type="ref">42</xref>, <xref rid="jah33201-bib-0043" ref-type="ref">43</xref> The dose of folic acid tested in the WAFACS, 2.5 mg/day, exceeded the tolerable upper intake level for folic acid of 1 mg/day.<xref rid="jah33201-bib-0044" ref-type="ref">44</xref> Consequently, approximately half of participants in the treated group had folate concentrations &gt;40 ng/mL at the end of study follow‐up, which is well above normal reference ranges for plasma folate.<xref rid="jah33201-bib-0045" ref-type="ref">45</xref>, <xref rid="jah33201-bib-0046" ref-type="ref">46</xref> Some have expressed concern that high folic acid concentrations may be proinflammatory and could perhaps counter any potential beneficial effect of folic acid supplementation.<xref rid="jah33201-bib-0011" ref-type="ref">11</xref>, <xref rid="jah33201-bib-0012" ref-type="ref">12</xref>, <xref rid="jah33201-bib-0047" ref-type="ref">47</xref> However, we found no evidence that high‐dose folic acid supplementation increased levels of inflammation as reflected by change in plasma concentration of any of the biomarkers examined. Moreover, we found no increased risk of chronic diseases associated with inflammation, including CVD, cancer, and diabetes mellitus, in WAFACS, nor was there an increase in all‐cause mortality in that trial.<xref rid="jah33201-bib-0005" ref-type="ref">5</xref>, <xref rid="jah33201-bib-0048" ref-type="ref">48</xref>, <xref rid="jah33201-bib-0049" ref-type="ref">49</xref>
</p>
              <p>The observation of a significant decrease in CRP, and increase in IL‐6, in the placebo group was unexpected. In exploratory analyses, we found that discontinuation of HRT use during follow‐up, perhaps in response to the disappointing results for HRT in the Women's Health Initiative in 2002,<xref rid="jah33201-bib-0050" ref-type="ref">50</xref> likely contributed to the decrease in CRP concentrations observed in both the placebo and treated groups. However, the clinical significance of the increase in IL‐6 in both groups is unclear, and discontinuation of HRT did not appear to materially alter plasma concentrations of IL‐6 or any of the other biomarkers examined.</p>
              <p>Several potential limitations of this substudy warrant consideration. Measurement of plasma biomarkers may not accurately reflect biomarker status at the cellular level. We also cannot exclude effects on other biomarkers of inflammation or endothelial function that were not measured. Participants in the WAFACS were at high risk of CVD, so the results may not be directly generalizable to the general population. It is also possible that the results would be different in populations with higher homocysteine levels than the WAFACS. Finally, this substudy suggests that approximately one third of participants in the WAFACS were folate deficient at the beginning of the trial, but this was virtually eliminated over the course of the study, perhaps attributed to background folic acid fortification in 1998. Therefore, we cannot rule out the possibility that this same treatment regimen might have resulted in an even greater reduction in homocysteine, and a different impact on inflammatory and endothelial function biomarkers in a more folate‐deficient, unfortified population.</p>
              <p>In summary, these substudy findings from a large, randomized trial of women at increased risk of CVD indicate that long‐term, combined treatment with folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> has no effect on plasma biomarkers of inflammation and endothelial dysfunction, despite significant reductions in plasma homocysteine. This may partly explain the absence of clinical benefit for homocysteine‐lowering in the WAFACS and other secondary prevention trials of CVD. The findings also appear consistent with a growing body of evidence that suggests that mildly or moderately elevated homocysteine may not be an important causal factor in vascular inflammation in patients at high risk for CVD, and that the association of homocysteine with CVD is unlikely to be attributed to chronic vascular inflammation.</p>
            </sec>
            <sec id="jah33201-sec-0029">
              <title>Sources of Funding</title>
              <p>This study was supported by grants HL46959 from the National Heart, Lung, and Blood Institute and EY06633 and EY18820 from the National Eye Institute.</p>
            </sec>
            <sec id="jah33201-sec-0030">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
          </body>
          <back>
            <ack id="jah33201-sec-0028">
              <title>Acknowledgments</title>
              <p>All study agents and their placebos, except for vitamin E, were provided by BASF Corporation (Mount Olive, NJ). Vitamin E and its placebo were provided by Cognis Corporation (LaGrange, IL). Pill packaging was provided by BASF and Cognis. BASF and Cognis did not participate in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the article.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah33201-bibl-0001">
              <title>References</title>
              <ref id="jah33201-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0001"><string-name><surname>Graham</surname><given-names>IM</given-names></string-name>, <string-name><surname>Daly</surname><given-names>LE</given-names></string-name>, <string-name><surname>Refsum</surname><given-names>HM</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>K</given-names></string-name>, <string-name><surname>Brattstrom</surname><given-names>LE</given-names></string-name>, <string-name><surname>Ueland</surname><given-names>PM</given-names></string-name>, <string-name><surname>Palma‐Reis</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Boers</surname><given-names>GH</given-names></string-name>, <string-name><surname>Sheahan</surname><given-names>RG</given-names></string-name>, <string-name><surname>Israelsson</surname><given-names>B</given-names></string-name>, <string-name><surname>Uiterwaal</surname><given-names>CS</given-names></string-name>, <string-name><surname>Meleady</surname><given-names>R</given-names></string-name>, <string-name><surname>McMaster</surname><given-names>D</given-names></string-name>, <string-name><surname>Verhoef</surname><given-names>P</given-names></string-name>, <string-name><surname>Witteman</surname><given-names>J</given-names></string-name>, <string-name><surname>Rubba</surname><given-names>P</given-names></string-name>, <string-name><surname>Bellet</surname><given-names>H</given-names></string-name>, <string-name><surname>Wautrecht</surname><given-names>JC</given-names></string-name>, <string-name><surname>de Valk</surname><given-names>HW</given-names></string-name>, <string-name><surname>Sales Luis</surname><given-names>AC</given-names></string-name>, <string-name><surname>Parrot‐Rouland</surname><given-names>FM</given-names></string-name>, <string-name><surname>Tan</surname><given-names>KS</given-names></string-name>, <string-name><surname>Higgins</surname><given-names>I</given-names></string-name>, <string-name><surname>Garcon</surname><given-names>D</given-names></string-name>, <string-name><surname>Andria</surname><given-names>G</given-names></string-name>. <article-title>Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project</article-title>. <source xml:lang="en">JAMA</source>. <year>1997</year>;<volume>277</volume>:<fpage>1775</fpage>–<lpage>1781</lpage>.<pub-id pub-id-type="pmid">9178790</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0002"><string-name><surname>Weiss</surname><given-names>N</given-names></string-name>, <string-name><surname>Keller</surname><given-names>C</given-names></string-name>, <string-name><surname>Hoffmann</surname><given-names>U</given-names></string-name>, <string-name><surname>Loscalzo</surname><given-names>J</given-names></string-name>. <article-title>Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia</article-title>. <source xml:lang="en">Vasc Med</source>. <year>2002</year>;<volume>7</volume>:<fpage>227</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">12553746</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0003"><collab collab-type="authors">Homocysteine Studies Collaboration</collab>
. <article-title>Homocysteine and risk of ischemic heart disease and stroke: a meta‐analysis</article-title>. <source xml:lang="en">JAMA</source>. <year>2002</year>;<volume>288</volume>:<fpage>2015</fpage>–<lpage>2022</lpage>.<pub-id pub-id-type="pmid">12387654</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0004"><string-name><surname>Welch</surname><given-names>GN</given-names></string-name>, <string-name><surname>Loscalzo</surname><given-names>J</given-names></string-name>. <article-title>Homocysteine and atherothrombosis</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>1998</year>;<volume>338</volume>:<fpage>1042</fpage>–<lpage>1050</lpage>.<pub-id pub-id-type="pmid">9535670</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0005"><string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Zaharris</surname><given-names>E</given-names></string-name>, <string-name><surname>MacFadyen</surname><given-names>J</given-names></string-name>, <string-name><surname>Danielson</surname><given-names>E</given-names></string-name>, <string-name><surname>Buring</surname><given-names>JE</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>. <article-title>Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2008</year>;<volume>299</volume>:<fpage>2027</fpage>–<lpage>2036</lpage>.<pub-id pub-id-type="pmid">18460663</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0006"><string-name><surname>Clarke</surname><given-names>R</given-names></string-name>, <string-name><surname>Halsey</surname><given-names>J</given-names></string-name>, <string-name><surname>Lewington</surname><given-names>S</given-names></string-name>, <string-name><surname>Lonn</surname><given-names>E</given-names></string-name>, <string-name><surname>Armitage</surname><given-names>J</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Bonaa</surname><given-names>KH</given-names></string-name>, <string-name><surname>Spence</surname><given-names>JD</given-names></string-name>, <string-name><surname>Nygard</surname><given-names>O</given-names></string-name>, <string-name><surname>Jamison</surname><given-names>R</given-names></string-name>, <string-name><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Guarino</surname><given-names>P</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>D</given-names></string-name>, <string-name><surname>Mir</surname><given-names>F</given-names></string-name>, <string-name><surname>Peto</surname><given-names>R</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>; <collab collab-type="authors">B‐Vitamin Treatment Trialists’ Collaboration</collab>
. <article-title>Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause‐specific mortality: meta‐analysis of 8 randomized trials involving 37 485 individuals</article-title>. <source xml:lang="en">Arch Intern Med</source>. <year>2010</year>;<volume>170</volume>:<fpage>1622</fpage>–<lpage>1631</lpage>.<pub-id pub-id-type="pmid">20937919</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0007"><string-name><surname>Marti‐Carvajal</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Sola</surname><given-names>I</given-names></string-name>, <string-name><surname>Lathyris</surname><given-names>D</given-names></string-name>. <article-title>Homocysteine‐lowering interventions for preventing cardiovascular events</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2015</year>;<volume>1</volume>:<fpage>CD006612</fpage>.<pub-id pub-id-type="pmid">25590290</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0008"><string-name><surname>Huang</surname><given-names>T</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Wahlqvist</surname><given-names>ML</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>. <article-title>Meta‐analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all‐cause mortality</article-title>. <source xml:lang="en">Clin Nutr</source>. <year>2012</year>;<volume>31</volume>:<fpage>448</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">22652362</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0009"><string-name><surname>Ji</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tan</surname><given-names>S</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chandra</surname><given-names>A</given-names></string-name>, <string-name><surname>Shi</surname><given-names>C</given-names></string-name>, <string-name><surname>Song</surname><given-names>B</given-names></string-name>, <string-name><surname>Qin</surname><given-names>J</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y</given-names></string-name>. <article-title>Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta‐analysis</article-title>. <source xml:lang="en">Neurology</source>. <year>2013</year>;<volume>81</volume>:<fpage>1298</fpage>–<lpage>1307</lpage>.<pub-id pub-id-type="pmid">24049135</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0010"><string-name><surname>Yang</surname><given-names>HT</given-names></string-name>, <string-name><surname>Lee</surname><given-names>M</given-names></string-name>, <string-name><surname>Hong</surname><given-names>KS</given-names></string-name>, <string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Saver</surname><given-names>JL</given-names></string-name>. <article-title>Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta‐analysis of randomized controlled trials</article-title>. <source xml:lang="en">Eur J Intern Med</source>. <year>2012</year>;<volume>23</volume>:<fpage>745</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">22884409</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0011"><string-name><surname>Smulders</surname><given-names>YM</given-names></string-name>, <string-name><surname>Blom</surname><given-names>HJ</given-names></string-name>. <article-title>The homocysteine controversy</article-title>. <source xml:lang="en">J Inherit Metab Dis</source>. <year>2011</year>;<volume>34</volume>:<fpage>93</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">20567905</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0012"><string-name><surname>van Dijk</surname><given-names>SC</given-names></string-name>, <string-name><surname>Enneman</surname><given-names>AW</given-names></string-name>, <string-name><surname>Swart</surname><given-names>KM</given-names></string-name>, <string-name><surname>van Wijngaarden</surname><given-names>JP</given-names></string-name>, <string-name><surname>Ham</surname><given-names>AC</given-names></string-name>, <string-name><surname>de Jonge</surname><given-names>R</given-names></string-name>, <string-name><surname>Blom</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Feskens</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Geleijnse</surname><given-names>JM</given-names></string-name>, <string-name><surname>van Schoor</surname><given-names>NM</given-names></string-name>, <string-name><surname>Dhonukshe‐Rutten</surname><given-names>RA</given-names></string-name>, <string-name><surname>de Jongh</surname><given-names>RT</given-names></string-name>, <string-name><surname>Lips</surname><given-names>P</given-names></string-name>, <string-name><surname>de Groot</surname><given-names>LC</given-names></string-name>, <string-name><surname>Uitterlinden</surname><given-names>AG</given-names></string-name>, <string-name><surname>van den Meiracker</surname><given-names>TH</given-names></string-name>, <string-name><surname>Mattace‐Raso</surname><given-names>FU</given-names></string-name>, <string-name><surname>van der Velde</surname><given-names>N</given-names></string-name>, <string-name><surname>Smulders</surname><given-names>YM</given-names></string-name>. <article-title>Effect of vitamin B12 and folic acid supplementation on biomarkers of endothelial function and inflammation among elderly individuals with hyperhomocysteinemia</article-title>. <source xml:lang="en">Vasc Med</source>. <year>2016</year>;<volume>21</volume>:<fpage>91</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">26774115</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0013"><string-name><surname>Baliga</surname><given-names>BS</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>T</given-names></string-name>, <string-name><surname>Fink</surname><given-names>LM</given-names></string-name>, <string-name><surname>Fonseca</surname><given-names>VA</given-names></string-name>. <article-title>Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine</article-title>. <source xml:lang="en">Endocr Pract</source>. <year>2000</year>;<volume>6</volume>:<fpage>435</fpage>–<lpage>441</lpage>.<pub-id pub-id-type="pmid">11155214</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0014"><string-name><surname>Bleie</surname><given-names>O</given-names></string-name>, <string-name><surname>Semb</surname><given-names>AG</given-names></string-name>, <string-name><surname>Grundt</surname><given-names>H</given-names></string-name>, <string-name><surname>Nordrehaug</surname><given-names>JE</given-names></string-name>, <string-name><surname>Vollset</surname><given-names>SE</given-names></string-name>, <string-name><surname>Ueland</surname><given-names>PM</given-names></string-name>, <string-name><surname>Nilsen</surname><given-names>DW</given-names></string-name>, <string-name><surname>Bakken</surname><given-names>AM</given-names></string-name>, <string-name><surname>Refsum</surname><given-names>H</given-names></string-name>, <string-name><surname>Nygard</surname><given-names>OK</given-names></string-name>. <article-title>Homocysteine‐lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease</article-title>. <source xml:lang="en">J Intern Med</source>. <year>2007</year>;<volume>262</volume>:<fpage>244</fpage>–<lpage>253</lpage>.<pub-id pub-id-type="pmid">17645592</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0015"><string-name><surname>Chang</surname><given-names>TY</given-names></string-name>, <string-name><surname>Chou</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Tseng</surname><given-names>CF</given-names></string-name>, <string-name><surname>Chung</surname><given-names>HM</given-names></string-name>, <string-name><surname>Fang</surname><given-names>HC</given-names></string-name>, <string-name><surname>Hung</surname><given-names>YM</given-names></string-name>, <string-name><surname>Wu</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Tzeng</surname><given-names>HM</given-names></string-name>, <string-name><surname>Lind</surname><given-names>CC</given-names></string-name>, <string-name><surname>Lu</surname><given-names>KC</given-names></string-name>. <article-title>Effects of folic acid and vitamin B complex on serum C‐reactive protein and albumin levels in stable hemodialysis patients</article-title>. <source xml:lang="en">Curr Med Res Opin</source>. <year>2007</year>;<volume>23</volume>:<fpage>1879</fpage>–<lpage>1886</lpage>.<pub-id pub-id-type="pmid">17605895</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0016"><string-name><surname>Chiang</surname><given-names>EP</given-names></string-name>, <string-name><surname>Selhub</surname><given-names>J</given-names></string-name>, <string-name><surname>Bagley</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Dallal</surname><given-names>G</given-names></string-name>, <string-name><surname>Roubenoff</surname><given-names>R</given-names></string-name>. <article-title>Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis</article-title>. <source xml:lang="en">Arthritis Res Ther</source>. <year>2005</year>;<volume>7</volume>:<fpage>R1404</fpage>–<lpage>R1411</lpage>.<pub-id pub-id-type="pmid">16277693</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0017"><string-name><surname>Durga</surname><given-names>J</given-names></string-name>, <string-name><surname>van Tits</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Schouten</surname><given-names>EG</given-names></string-name>, <string-name><surname>Kok</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Verhoef</surname><given-names>P</given-names></string-name>. <article-title>Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial</article-title>. <source xml:lang="en">Arch Intern Med</source>. <year>2005</year>;<volume>165</volume>:<fpage>1388</fpage>–<lpage>1394</lpage>.<pub-id pub-id-type="pmid">15983288</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0018"><string-name><surname>Dusitanond</surname><given-names>P</given-names></string-name>, <string-name><surname>Eikelboom</surname><given-names>JW</given-names></string-name>, <string-name><surname>Hankey</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Thom</surname><given-names>J</given-names></string-name>, <string-name><surname>Gilmore</surname><given-names>G</given-names></string-name>, <string-name><surname>Loh</surname><given-names>K</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Q</given-names></string-name>, <string-name><surname>Klijn</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Langton</surname><given-names>P</given-names></string-name>, <string-name><surname>van Bockxmeer</surname><given-names>FM</given-names></string-name>, <string-name><surname>Baker</surname><given-names>R</given-names></string-name>, <string-name><surname>Jamrozik</surname><given-names>K</given-names></string-name>. <article-title>Homocysteine‐lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial</article-title>. <source xml:lang="en">Stroke</source>. <year>2005</year>;<volume>36</volume>:<fpage>144</fpage>–<lpage>146</lpage>.<pub-id pub-id-type="pmid">15569860</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0019"><string-name><surname>Klerk</surname><given-names>M</given-names></string-name>, <string-name><surname>Durga</surname><given-names>J</given-names></string-name>, <string-name><surname>Schouten</surname><given-names>EG</given-names></string-name>, <string-name><surname>Kluft</surname><given-names>C</given-names></string-name>, <string-name><surname>Kok</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Verhoef</surname><given-names>P</given-names></string-name>. <article-title>No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C‐reactive protein in older adults</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2005</year>;<volume>94</volume>:<fpage>96</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">16113791</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0020"><string-name><surname>Mangoni</surname><given-names>AA</given-names></string-name>, <string-name><surname>Arya</surname><given-names>R</given-names></string-name>, <string-name><surname>Ford</surname><given-names>E</given-names></string-name>, <string-name><surname>Asonganyi</surname><given-names>B</given-names></string-name>, <string-name><surname>Sherwood</surname><given-names>RA</given-names></string-name>, <string-name><surname>Ouldred</surname><given-names>E</given-names></string-name>, <string-name><surname>Swift</surname><given-names>CG</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>SH</given-names></string-name>. <article-title>Effects of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomised controlled trial</article-title>. <source xml:lang="en">Thromb Res</source>. <year>2003</year>;<volume>110</volume>:<fpage>13</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">12877903</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0021"><string-name><surname>Peeters</surname><given-names>AC</given-names></string-name>, <string-name><surname>van Aken</surname><given-names>BE</given-names></string-name>, <string-name><surname>Blom</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Reitsma</surname><given-names>PH</given-names></string-name>, <string-name><surname>den Heijer</surname><given-names>M</given-names></string-name>. <article-title>The effect of homocysteine reduction by B‐vitamin supplementation on inflammatory markers</article-title>. <source xml:lang="en">Clin Chem Lab Med</source>. <year>2007</year>;<volume>45</volume>:<fpage>54</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">17243915</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0022"><string-name><surname>Schernthaner</surname><given-names>GH</given-names></string-name>, <string-name><surname>Plank</surname><given-names>C</given-names></string-name>, <string-name><surname>Minar</surname><given-names>E</given-names></string-name>, <string-name><surname>Bieglmayer</surname><given-names>C</given-names></string-name>, <string-name><surname>Koppensteiner</surname><given-names>R</given-names></string-name>, <string-name><surname>Schernthaner</surname><given-names>G</given-names></string-name>. <article-title>No effect of homocysteine‐lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease</article-title>. <source xml:lang="en">Eur J Clin Invest</source>. <year>2006</year>;<volume>36</volume>:<fpage>333</fpage>–<lpage>339</lpage>.<pub-id pub-id-type="pmid">16634837</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0023"><string-name><surname>Solini</surname><given-names>A</given-names></string-name>, <string-name><surname>Santini</surname><given-names>E</given-names></string-name>, <string-name><surname>Ferrannini</surname><given-names>E</given-names></string-name>. <article-title>Effect of short‐term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects</article-title>. <source xml:lang="en">Int J Obes</source>. <year>2006</year>;<volume>30</volume>:<fpage>1197</fpage>–<lpage>1202</lpage>.</mixed-citation>
              </ref>
              <ref id="jah33201-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0024"><string-name><surname>Spoelstra‐de</surname><given-names>MA</given-names></string-name>, <string-name><surname>Brouwer</surname><given-names>CB</given-names></string-name>, <string-name><surname>Terheggen</surname><given-names>F</given-names></string-name>, <string-name><surname>Bollen</surname><given-names>JM</given-names></string-name>, <string-name><surname>Stehouwer</surname><given-names>CD</given-names></string-name>, <string-name><surname>Smulders</surname><given-names>YM</given-names></string-name>. <article-title>No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia</article-title>. <source xml:lang="en">Neth J Med</source>. <year>2004</year>;<volume>62</volume>:<fpage>246</fpage>–<lpage>253</lpage>.<pub-id pub-id-type="pmid">15554600</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0025"><string-name><surname>Ullegaddi</surname><given-names>R</given-names></string-name>, <string-name><surname>Powers</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Gariballa</surname><given-names>SE</given-names></string-name>. <article-title>B‐group vitamin supplementation mitigates oxidative damage after acute ischaemic stroke</article-title>. <source xml:lang="en">Clin Sci</source>. <year>2004</year>;<volume>107</volume>:<fpage>477</fpage>–<lpage>484</lpage>.<pub-id pub-id-type="pmid">15279619</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0026"><string-name><surname>Vermeulen</surname><given-names>EG</given-names></string-name>, <string-name><surname>Rauwerda</surname><given-names>JA</given-names></string-name>, <string-name><surname>van den Berg</surname><given-names>M</given-names></string-name>, <string-name><surname>de Jong</surname><given-names>SC</given-names></string-name>, <string-name><surname>Schalkwijk</surname><given-names>C</given-names></string-name>, <string-name><surname>Twisk</surname><given-names>JW</given-names></string-name>, <string-name><surname>Stehouwer</surname><given-names>CD</given-names></string-name>. <article-title>Homocysteine‐lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C‐reactive protein: further analysis of secondary end‐points of a randomized clinical trial</article-title>. <source xml:lang="en">Eur J Clin Invest</source>. <year>2003</year>;<volume>33</volume>:<fpage>209</fpage>–<lpage>215</lpage>.<pub-id pub-id-type="pmid">12641538</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0027"><string-name><surname>Ziegler</surname><given-names>S</given-names></string-name>, <string-name><surname>Mittermayer</surname><given-names>F</given-names></string-name>, <string-name><surname>Plank</surname><given-names>C</given-names></string-name>, <string-name><surname>Minar</surname><given-names>E</given-names></string-name>, <string-name><surname>Wolzt</surname><given-names>M</given-names></string-name>, <string-name><surname>Schernthaner</surname><given-names>GH</given-names></string-name>. <article-title>Homocyst(e)ine‐lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2005</year>;<volume>90</volume>:<fpage>2175</fpage>–<lpage>2178</lpage>.<pub-id pub-id-type="pmid">15634723</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0028"><string-name><surname>Jonasson</surname><given-names>T</given-names></string-name>, <string-name><surname>Ohlin</surname><given-names>AK</given-names></string-name>, <string-name><surname>Gottsater</surname><given-names>A</given-names></string-name>, <string-name><surname>Hultberg</surname><given-names>B</given-names></string-name>, <string-name><surname>Ohlin</surname><given-names>H</given-names></string-name>. <article-title>Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease—a prospective randomized study of vitamin supplementation</article-title>. <source xml:lang="en">Clin Chem Lab Med</source>. <year>2005</year>;<volume>43</volume>:<fpage>628</fpage>–<lpage>634</lpage>.<pub-id pub-id-type="pmid">16006259</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0029"><string-name><surname>Title</surname><given-names>LM</given-names></string-name>, <string-name><surname>Ur</surname><given-names>E</given-names></string-name>, <string-name><surname>Giddens</surname><given-names>K</given-names></string-name>, <string-name><surname>McQueen</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Nassar</surname><given-names>BA</given-names></string-name>. <article-title>Folic acid improves endothelial dysfunction in type 2 diabetes—an effect independent of homocysteine‐lowering</article-title>. <source xml:lang="en">Vasc Med</source>. <year>2006</year>;<volume>11</volume>:<fpage>101</fpage>–<lpage>109</lpage>.<pub-id pub-id-type="pmid">16886840</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0030"><string-name><surname>Bassuk</surname><given-names>SS</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Lee</surname><given-names>IM</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Christen</surname><given-names>WG</given-names></string-name>, <string-name><surname>Bubes</surname><given-names>VY</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>DS</given-names></string-name>, <string-name><surname>Copeland</surname><given-names>T</given-names></string-name>, <string-name><surname>Friedenberg</surname><given-names>G</given-names></string-name>, <string-name><surname>D'Agostino</surname><given-names>DM</given-names></string-name>, <string-name><surname>Ridge</surname><given-names>CY</given-names></string-name>, <string-name><surname>MacFadyen</surname><given-names>JG</given-names></string-name>, <string-name><surname>Kalan</surname><given-names>K</given-names></string-name>, <string-name><surname>Buring</surname><given-names>JE</given-names></string-name>. <article-title>Baseline characteristics of participants in the vitamin D and omega‐3 trial (VITAL)</article-title>. <source xml:lang="en">Contemp Clin Trials</source>. <year>2016</year>;<volume>47</volume>:<fpage>235</fpage>–<lpage>243</lpage>.<pub-id pub-id-type="pmid">26767629</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0031"><string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Zaharris</surname><given-names>E</given-names></string-name>, <string-name><surname>MacFadyen</surname><given-names>J</given-names></string-name>, <string-name><surname>Danielson</surname><given-names>E</given-names></string-name>, <string-name><surname>Buring</surname><given-names>JE</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>. <article-title>A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study</article-title>. <source xml:lang="en">Arch Intern Med</source>. <year>2007</year>;<volume>167</volume>:<fpage>1610</fpage>–<lpage>1618</lpage>.<pub-id pub-id-type="pmid">17698683</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0032"><string-name><surname>Pradhan</surname><given-names>AD</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Rossouw</surname><given-names>JE</given-names></string-name>, <string-name><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name><surname>Mouton</surname><given-names>CP</given-names></string-name>, <string-name><surname>Rifai</surname><given-names>N</given-names></string-name>, <string-name><surname>Wallace</surname><given-names>RB</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>RD</given-names></string-name>, <string-name><surname>Pettinger</surname><given-names>MB</given-names></string-name>, <string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>. <article-title>Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study</article-title>. <source xml:lang="en">JAMA</source>. <year>2002</year>;<volume>288</volume>:<fpage>980</fpage>–<lpage>987</lpage>.<pub-id pub-id-type="pmid">12190368</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0033"><string-name><surname>Silvestri</surname><given-names>A</given-names></string-name>, <string-name><surname>Gebara</surname><given-names>O</given-names></string-name>, <string-name><surname>Vitale</surname><given-names>C</given-names></string-name>, <string-name><surname>Wajngarten</surname><given-names>M</given-names></string-name>, <string-name><surname>Leonardo</surname><given-names>F</given-names></string-name>, <string-name><surname>Ramires</surname><given-names>JA</given-names></string-name>, <string-name><surname>Fini</surname><given-names>M</given-names></string-name>, <string-name><surname>Mercuro</surname><given-names>G</given-names></string-name>, <string-name><surname>Rosano</surname><given-names>GM</given-names></string-name>. <article-title>Increased levels of C‐reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response</article-title>. <source xml:lang="en">Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>3165</fpage>–<lpage>3169</lpage>.<pub-id pub-id-type="pmid">12796135</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0034"><string-name><surname>Lawson</surname><given-names>C</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>S</given-names></string-name>. <article-title>ICAM‐1 signaling in endothelial cells</article-title>. <source xml:lang="en">Pharmacol Rep</source>. <year>2009</year>;<volume>61</volume>:<fpage>22</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">19307690</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0035"><string-name><surname>Gori</surname><given-names>AM</given-names></string-name>, <string-name><surname>Corsi</surname><given-names>AM</given-names></string-name>, <string-name><surname>Fedi</surname><given-names>S</given-names></string-name>, <string-name><surname>Gazzini</surname><given-names>A</given-names></string-name>, <string-name><surname>Sofi</surname><given-names>F</given-names></string-name>, <string-name><surname>Bartali</surname><given-names>B</given-names></string-name>, <string-name><surname>Bandinelli</surname><given-names>S</given-names></string-name>, <string-name><surname>Gensini</surname><given-names>GF</given-names></string-name>, <string-name><surname>Abbate</surname><given-names>R</given-names></string-name>, <string-name><surname>Ferrucci</surname><given-names>L</given-names></string-name>. <article-title>A proinflammatory state is associated with hyperhomocysteinemia in the elderly</article-title>. <source xml:lang="en">Am J Clin Nutr</source>. <year>2005</year>;<volume>82</volume>:<fpage>335</fpage>–<lpage>341</lpage>.<pub-id pub-id-type="pmid">16087976</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0036"><string-name><surname>Erren</surname><given-names>M</given-names></string-name>, <string-name><surname>Reinecke</surname><given-names>H</given-names></string-name>, <string-name><surname>Junker</surname><given-names>R</given-names></string-name>, <string-name><surname>Fobker</surname><given-names>M</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>H</given-names></string-name>, <string-name><surname>Schurek</surname><given-names>JO</given-names></string-name>, <string-name><surname>Kropf</surname><given-names>J</given-names></string-name>, <string-name><surname>Kerber</surname><given-names>S</given-names></string-name>, <string-name><surname>Breithardt</surname><given-names>G</given-names></string-name>, <string-name><surname>Assmann</surname><given-names>G</given-names></string-name>, <string-name><surname>Cullen</surname><given-names>P</given-names></string-name>. <article-title>Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries</article-title>. <source xml:lang="en">Arterioscler Thromb Vasc Biol</source>. <year>1999</year>;<volume>19</volume>:<fpage>2355</fpage>–<lpage>2363</lpage>.<pub-id pub-id-type="pmid">10521364</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0037"><string-name><surname>Becker</surname><given-names>A</given-names></string-name>, <string-name><surname>Van Hinsbergh</surname><given-names>VW</given-names></string-name>, <string-name><surname>Kostense</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Jager</surname><given-names>A</given-names></string-name>, <string-name><surname>Dekker</surname><given-names>JM</given-names></string-name>, <string-name><surname>Nijpels</surname><given-names>G</given-names></string-name>, <string-name><surname>Heine</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Bouter</surname><given-names>LM</given-names></string-name>, <string-name><surname>Stehouwer</surname><given-names>CD</given-names></string-name>. <article-title>Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C‐reactive protein in type 2 diabetic and non‐diabetic subjects—the Hoorn Study</article-title>. <source xml:lang="en">Eur J Clin Invest</source>. <year>2000</year>;<volume>30</volume>:<fpage>763</fpage>–<lpage>770</lpage>.<pub-id pub-id-type="pmid">10998075</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0038"><string-name><surname>Akalin</surname><given-names>A</given-names></string-name>, <string-name><surname>Alatas</surname><given-names>O</given-names></string-name>, <string-name><surname>Colak</surname><given-names>O</given-names></string-name>. <article-title>Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients</article-title>. <source xml:lang="en">Eur J Endocrinol</source>. <year>2008</year>;<volume>158</volume>:<fpage>47</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">18166816</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0039"><string-name><surname>Folsom</surname><given-names>AR</given-names></string-name>, <string-name><surname>Desvarieux</surname><given-names>M</given-names></string-name>, <string-name><surname>Nieto</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Boland</surname><given-names>LL</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Chambless</surname><given-names>LE</given-names></string-name>. <article-title>B vitamin status and inflammatory markers</article-title>. <source xml:lang="en">Atherosclerosis</source>. <year>2003</year>;<volume>169</volume>:<fpage>169</fpage>–<lpage>174</lpage>.<pub-id pub-id-type="pmid">12860264</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0040"><string-name><surname>Holven</surname><given-names>KB</given-names></string-name>, <string-name><surname>Aukrust</surname><given-names>P</given-names></string-name>, <string-name><surname>Retterstol</surname><given-names>K</given-names></string-name>, <string-name><surname>Hagve</surname><given-names>TA</given-names></string-name>, <string-name><surname>Morkrid</surname><given-names>L</given-names></string-name>, <string-name><surname>Ose</surname><given-names>L</given-names></string-name>, <string-name><surname>Nenseter</surname><given-names>MS</given-names></string-name>. <article-title>Increased levels of C‐reactive protein and interleukin‐6 in hyperhomocysteinemic subjects</article-title>. <source xml:lang="en">Scand J Clin Lab Invest</source>. <year>2006</year>;<volume>66</volume>:<fpage>45</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">16464786</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0041"><article-title>Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid (21 CFR 136, 137, and 139). Final rule</article-title>. <source xml:lang="en">Fed Regist</source>. <year>1996</year>;<volume>61</volume>:<fpage>8781</fpage>–<lpage>8797</lpage>.</mixed-citation>
              </ref>
              <ref id="jah33201-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0042"><string-name><surname>Jacques</surname><given-names>PF</given-names></string-name>, <string-name><surname>Selhub</surname><given-names>J</given-names></string-name>, <string-name><surname>Bostom</surname><given-names>AG</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>PW</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>IH</given-names></string-name>. <article-title>The effect of folic acid fortification on plasma folate and total homocysteine concentrations</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>1999</year>;<volume>340</volume>:<fpage>1449</fpage>–<lpage>1454</lpage>.<pub-id pub-id-type="pmid">10320382</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0043"><string-name><surname>Dietrich</surname><given-names>M</given-names></string-name>, <string-name><surname>Brown</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Block</surname><given-names>G</given-names></string-name>. <article-title>The effect of folate fortification of cereal‐grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non‐supplement users in the United States</article-title>. <source xml:lang="en">J Am Coll Nutr</source>. <year>2005</year>;<volume>24</volume>:<fpage>266</fpage>–<lpage>274</lpage>.<pub-id pub-id-type="pmid">16093404</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="book" id="jah33201-cit-0044"><collab collab-type="authors">Food and Nutrition Board</collab>
. <source xml:lang="en">Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. A Report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients. Institute of Medicine</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academy Press</publisher-name>; <year>1998</year>.</mixed-citation>
              </ref>
              <ref id="jah33201-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0045"><string-name><surname>de Benoist</surname><given-names>B</given-names></string-name>. <article-title>Conclusions of a WHO technical consultation on folate and vitamin B12 deficiencies</article-title>. <source xml:lang="en">Food Nutr Bull</source>. <year>2008</year>;<volume>29</volume>:<fpage>S238</fpage>–<lpage>S244</lpage>.<pub-id pub-id-type="pmid">18709899</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0046"><string-name><surname>Selhub</surname><given-names>J</given-names></string-name>, <string-name><surname>Jacques</surname><given-names>PF</given-names></string-name>, <string-name><surname>Dallal</surname><given-names>G</given-names></string-name>, <string-name><surname>Choumenkovitch</surname><given-names>S</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>G</given-names></string-name>. <article-title>The use of blood concentrations of vitamins and their respective functional indicators to define folate and vitamin B12 status</article-title>. <source xml:lang="en">Food Nutr Bull</source>. <year>2008</year>;<volume>29</volume>:<fpage>S67</fpage>–<lpage>S73</lpage>.<pub-id pub-id-type="pmid">18709882</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0047"><string-name><surname>Kelly</surname><given-names>KB</given-names></string-name>, <string-name><surname>Kennelly</surname><given-names>JP</given-names></string-name>, <string-name><surname>Ordonez</surname><given-names>M</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>R</given-names></string-name>, <string-name><surname>Leonard</surname><given-names>K</given-names></string-name>, <string-name><surname>Stabler</surname><given-names>S</given-names></string-name>, <string-name><surname>Gomez‐Munoz</surname><given-names>A</given-names></string-name>, <string-name><surname>Field</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>RL</given-names></string-name>. <article-title>Excess folic acid increases lipid storage, weight gain, and adipose tissue inflammation in high fat diet‐fed rats</article-title>. <source xml:lang="en">Nutrients</source>. <year>2016</year>;<volume>8</volume>:<fpage>E594</fpage>.<pub-id pub-id-type="pmid">27669293</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0048"><string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Van Denburgh</surname><given-names>M</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>. <article-title>Effect of homocysteine‐lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial</article-title>. <source xml:lang="en">Diabetes</source>. <year>2009</year>;<volume>58</volume>:<fpage>1921</fpage>–<lpage>1928</lpage>.<pub-id pub-id-type="pmid">19491213</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0049"><string-name><surname>Zhang</surname><given-names>SM</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Buring</surname><given-names>JE</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>. <article-title>Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2008</year>;<volume>300</volume>:<fpage>2012</fpage>–<lpage>2021</lpage>.<pub-id pub-id-type="pmid">18984888</pub-id></mixed-citation>
              </ref>
              <ref id="jah33201-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="jah33201-cit-0050"><string-name><surname>Rossouw</surname><given-names>JE</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>GL</given-names></string-name>, <string-name><surname>Prentice</surname><given-names>RL</given-names></string-name>, <string-name><surname>LaCroix</surname><given-names>AZ</given-names></string-name>, <string-name><surname>Kooperberg</surname><given-names>C</given-names></string-name>, <string-name><surname>Stefanick</surname><given-names>ML</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>RD</given-names></string-name>, <string-name><surname>Beresford</surname><given-names>SA</given-names></string-name>, <string-name><surname>Howard</surname><given-names>BV</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KC</given-names></string-name>, <string-name><surname>Kotchen</surname><given-names>JM</given-names></string-name>, <string-name><surname>Ockene</surname><given-names>J</given-names></string-name>; <collab collab-type="authors">Writing Group for the Women's Health Initiative Investigators</collab>
. <article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2002</year>;<volume>288</volume>:<fpage>321</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">12117397</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
